ArticleCancer medicine2023

Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.

Brandon Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.